The magnitude of the EPS beat (39.4%) combined with a second consecutive guidance raise signals accelerating fundamental momentum, particularly in the Health Care Benefits segment. Traders should watch for continued margin improvement in H2 2026 and monitor medical cost trends, as management maintains a cautious view on elevated cost trends and macro headwinds. The raised cash flow guidance to at least $11.5B provides significant capital return flexibility.
Price Chart
Executive Summary
CVS Health reported strong Q2 2026 results with total revenues of $106.1 billion (+7.3% YoY) and Adjusted EPS of $2.58, significantly beating the $1.85 consensus. The company raised full-year 2026 guidance across all key metrics, driven by continued margin recovery in the Health Care Benefits segment and broad-based operational strength. This marks a second consecutive quarter of raised guidance, reinforcing the turnaround narrative.
Key Financial Metrics
Key Facts
- Q2 2026 total revenues of $106.1 billion, up 7.3% year-over-year
- Adjusted EPS of $2.58 vs consensus of $1.85 (beat by 39.4%)
- GAAP diluted EPS of $2.31 vs $0.80 in prior year
- Full-year 2026 GAAP EPS guidance raised to $6.84-$7.04 from $6.24-$6.44
- Full-year 2026 Adjusted EPS guidance raised to $7.90-$8.10 from $7.30-$7.50
- Cash flow from operations guidance raised to at least $11.5 billion from at least $9.5 billion
- Health Care Benefits segment adjusted operating income increased 85.5% YoY
- Medical benefit ratio improved to 87.4% from 89.9% in prior year
- Year-to-date cash flow from operations of $10.6 billion
Financial Impact
Full-year 2026 Adjusted EPS guidance raised by $0.60 at midpoint ($7.90-$8.10 vs prior $7.30-$7.50), representing ~8% increase
Risk Factors
- Continued elevated health care cost trends could pressure margins in H2 2026
- Potential macro headwinds and pharmacy reimbursement pressure
- Medical membership declined 0.7M YoY due to exit from individual exchange business
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000064803-26-000097 |
| Document: cvs-20260805.htm | 0000064803-26-000097 |
| Document: 0000064803-26-000097-index-headers.html | 0000064803-26-000097 |
| Document: 0000064803-26-000097-index.html | 0000064803-26-000097 |
| Document: 0000064803-26-000097.txt | 0000064803-26-000097 |
| 8-K Data (Synthetic) | 0000064803-26-000097 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $99.12 $97.23 | ▼ −1.91% | ▼ −1.31% | $85.20 (−14.04%) |
Jul 10, 2026 11w ago | Press Release | $104.15 $95.46 | ▼ −8.35% | ▼ −10.77% | $85.20 (−18.19%) |
Jun 29, 2026 13w ago | Court Ruling | $103.58 $107.74 | ▲ +4.02% | ▲ +4.30% | $85.20 (−17.74%) |
May 22, 2026 18w ago | S-3ASR | $90.55 $101.57 | ▲ +12.17% | ▲ +14.44% | $85.20 (−5.91%) |
May 19, 2026 19w ago | Court Ruling | $93.11 $99.16 | ▲ +6.50% | ▲ +6.54% | $85.20 (−8.49%) |
May 15, 2026 20w ago | Court Ruling | $95.88 $100.68 | ▲ +5.01% | ▲ +2.89% | $85.20 (−11.14%) |
May 6, 2026 21w ago | 8-K | $86.76 $91.37 | ▲ +5.32% | ▲ +2.54% | $85.20 (−1.79%) |
May 4, 2026 21w ago | Court Ruling | $82.01 $89.50 | ▲ +9.13% | ▲ +3.34% | $85.20 (+3.89%) |
Apr 29, 2026 22w ago | Court Ruling | $83.84 $92.97 | ▲ +10.89% | ▲ +4.85% | $85.20 (+1.62%) |
Apr 14, 2026 24w ago | Court Ruling | $77.60 $92.22 | ▼ −18.85% | ▼ −12.55% | $85.20 (−9.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access